NUS reported revenue, adj NI, and adj EPS of $370.3M, $14.5M, and $0.29, respectively. This compares to our estimates of $380.2M, $15.1M, and $0.30, respectively. These results were at the low end of revenue guidance and the high end of EPS guidance. Rhyz delivered $48.52M of revenue, including $42.45M from Manufacturing and $6.07M from Rhyz Other, while the Nu Skin business posted 77.6% gross margin and continued to benefit from disciplined spending as selling expense declined to 40.8% of the core business. Management highlighted strategic and active penetration into India and other emerging countries, along with overall margin expansion and a one-time tax benefit, as key contributors to EPS results in FY25. Despite weaker-than-expected top-line results, management remains focused on executing its strategic initiatives